Observed performance metrics in laboratory models
Observed performance metrics in laboratory models
Free shipping worldwide on all orders. This includes delivery to APO, DPO & FPO addresses.
Domestic: 5-7 business days.
International: 10-14 business days.
No express shipping due to timing inconsistencies from couriers.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
Unordered list
Bold text
Emphasis
Superscript
Subscript
Research summary on Ostarine (also known as MK-2866).
Ostarine, also known as Enobosarm or MK-2866, is a non-steroidal selective androgen receptor modulator.
Ostarine (MK-2866) is a Selective Androgen Receptor Modulator (SARM) — which means it selectivelybinds to androgen receptors in muscle and bone tissue, promoting anabolic activity without the samelevel of androgenic effects seen with traditional anabolic steroids.
In research settings, it has been shown to:
✔ Increase lean muscle mass while in a caloric deficit.
✔ Improve muscle strength and functional performance
✔ Support bone density and joint health during periods of muscle atrophy risk.
📏 LEAN MUSCLE RETENTION:
In studies, Ostarine has demonstrated the ability to preserve and even increase lean muscle massduring periods of calorie restriction or immobilization, helping maintain strength and physicalperformance.
🛠️ BONE & JOINT SUPPORT:
Ostarine has shown positive effects on bone mineral density and may support joint health, potentially reducing injury risk during high-intensity training or rehabilitation.
⚡ FUNCTIONAL PERFORMANCE:
By enhancing anabolic signaling in muscle tissue, Ostarine can improve endurance, recovery rate, andoverall functional output without significantly increasing water retention or fat mass.
1. Dalton JT et al., 2011 — Double-blind phase II in healthy elderly men & postmenopausal women
2. Dobs AS et al., 2013 — Phase II RCT in cancer patients with muscle wasting
3. Coss CC et al., 2016 — Clinical pharmacokinetic drug–drug interactionstudies
Explore the best stack options.